# Study Evaluating SARS-CoV-2 (COVID-19) Humoral Response After BNT162b2 Vaccine in Immunocompromised Adults Compared to Healthy Adults

> **NCT04952766** · PHASE4 · COMPLETED · sponsor: **Centre Hospitalier Régional d'Orléans** · enrollment: 196 (actual)

## Conditions studied

- Kidney Transplant
- Myeloma
- Cancer
- Hematologic Malignancy
- Multiple Sclerosis
- Hypergammaglobulinemia
- Malignant Tumor
- Hiv
- Diabetes Type 2

## Interventions

- **BIOLOGICAL:** Biological samples

## Key facts

- **NCT ID:** NCT04952766
- **Lead sponsor:** Centre Hospitalier Régional d'Orléans
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-03-26
- **Primary completion:** 2022-02-06
- **Final completion:** 2022-02-06
- **Target enrollment:** 196 (ACTUAL)
- **Last updated:** 2025-12-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04952766

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04952766, "Study Evaluating SARS-CoV-2 (COVID-19) Humoral Response After BNT162b2 Vaccine in Immunocompromised Adults Compared to Healthy Adults". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT04952766. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*